Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women's Health

CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced a strategic research collaboration with ASKA Pharmaceutical Co., Ltd. ("ASKA"), a specialized pharmaceutical company with a strong focus on internal medicine, obstetrics, and gynecology. This partnership aims to identify novel therapeutic targets with high drug development potential for challenging gynecological conditions, including endometriosis, uterine fibroids, and adenomyosis, by leveraging Insilico's proprietary AI-driven target identification engine, PandaOmics.

Gynecological diseases have long posed challenges, including difficult diagnosis, limited treatment options, and a substantial disease burden, affecting millions of patients worldwide. According to estimates from the World Health Organization, endometriosis affects approximately 190 million women globally, while uterine fibroids and adenomyosis impact an even larger demographic, often co-occurring and heavily impacting women's reproductive health.

This collaboration combines ASKA's deep expertise in gynecological therapeutics with Insilico Medicine's advanced AI-driven biological analytics capabilities to address major unmet medical needs affecting hundreds of millions of patients worldwide and to accelerate the development of innovative solutions. Under the partnership, Insilico will leverage PandaOmics to identify and explore disease hypotheses, while ASKA will validate the AI-predicted therapeutic targets with high translational potential.

The project will be led by the Target Discovery team with Dr. Frank Pun, Head of Insilico Medicine's Hong Kong site. The team recently unveiled Target Identification Pro (TargetPro), an AI-driven framework that accelerates therapeutic target discovery by integrating multi-modal data into disease-specific models. By identifying context-dependent predictive patterns, TargetPro outperforms existing target identification models in accurately predicting which targets are most likely to advance to clinical stages. The framework goes beyond validating established clinical targets to nominate novel, high-potential candidates optimized for immediate preclinical validation.

"I am honored to lead this collaboration with ASKA," said Dr. Frank Pun. "The preclinical validation of our previously AI-nominated targets of endometriosis demonstrates that AI can uncover actionable insights within the complex biological landscape of women's disease. With our latest disease-specific TargetPro models, we look forward to helping ASKA develop the next generation of treatments for women worldwide."

Dr. Shuzo Watanabe, Head of the Innovative Drug Discovery Research Division Director, stated:

 "We are very pleased to announce our collaboration with Insilico Medicine. At ASKA Pharmaceutical, we aim to accelerate the drug discovery process by leveraging AI across all stages of research and development. Through this partnership with Insilico Medicine, we hope to rapidly identify high quality and highly promising drug discovery targets."

Notably, ASKA has been a long-term user of Insilico's AI software. Through this expanded partnership, Insilico and ASKA will apply these proven AI methodologies to navigate the complex biological landscapes of endometriosis, uterine fibroids and adenomyosis, providing a clear roadmap for the next generation of treatments, further underscoring both parties' shared commitment and aligned goals to advance innovation in women's health.

About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code HKEX: 03696.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com

About ASKA Pharmaceutical
ASKA Pharmaceutical operates under the corporate philosophy of "Contribute toward the improvement of people's health and progress in medicine through the development of innovative products," and focuses on internal medicine (gastroenterology, thyroid), obstetrics and gynecology, and urology. The company is committed to becoming a competitive specialty pharma company by centering its business on the development of innovative drugs. We will solidify our position as a competitive specialty pharma company and, based on our contributions through pharmaceuticals, contribute to people's health by responding to changing social needs. For more details, please visit its website. https://www.aska-pharma.co.jp/english/

SOURCE Insilico Medicine